The Promising Role of Targeted Therapies for the Treatment of X-Linked Hypophosphatemia and Tumor-Induced Osteomalacia: Key Considerations for Pharmacists
Ultragenyx Pharmaceutical Inc.
Faculty
Sharon K. Park, PharmD, MEd, BCPS
Associate Professor
Department of Clinical and Administrative Sciences
School of Pharmacy
Notre Dame of Maryland University
Baltimore, Maryland
Clinical Pharmacy Specialist
Drug Information and Medication Use Policy
The Johns Hopkins Hospital
Baltimore, Maryland
Program Description
Patients with tumor-induced osteomalacia (TIO) and X-linked hypophosphatemia (XLH) generally present with signs and symptoms of chronic hypophosphatemia including bone pain, weakness, and fractures. These nonspecific symptoms may frequently delay diagnosis and initiation of treatment by months or years. As key members of the multidisciplinary team, pharmacists are optimally positioned to recognize the complexities surrounding available therapies and educate patients about adverse effect management and other challenges they may encounter in managing TIO and XLH with either supplementation or pharmacologic treatment. Newer, targeted therapies have the potential to change the landscape of management of TIO and XLH, making it essential for pharmacists to be familiar with the pathophysiology, clinical presentation, and complications associated with these conditions. Pharmacists have an important role in facilitating dosing and administration of therapy for these rare conditions. They must be knowledgeable about the benefits and risks of current and emerging therapy options and treatment strategies for TIO and XLH. This activity will review evolving research in treatment and management of these conditions, and the role of pharmacists in significantly contributing to improving quality of life and reducing health care costs for patients with TIO and XLH.
Target Audience: Specialty pharmacists
Type of Activity: Application
Release date: April 26, 2021
Expiration date: December 15, 2022
Time to complete activity: 2.0 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Investigate the epidemiology, pathophysiology, commonalities, and challenges associated with tumor-induced osteomalacia (TIO) and X-linked hypophosphatemia (XLH)
- Illustrate the disease burden of TIO and XLH, as well as challenges and limitations associated with conventional therapies and the impact on patient quality of life
- Explore the efficacy and safety data associated with new and emerging targeted therapies
- Identify the role of the pharmacist in making clinical recommendations to improve management and clinical outcomes in those with TIO and XLH
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-21-096-H01-P. The activity is available for CE credit through December 15, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Sharon K. Park, PharmD, MEd, BCPS, has no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHCP; Ann Marciano; Susan Pordon; and Brianna Winters
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information:
